Literature DB >> 22403061

Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling.

Hong Wei1, Djahida Bedja, Norimichi Koitabashi, Dongmei Xing, Jasper Chen, Karen Fox-Talbot, Rosanne Rouf, Shaoping Chen, Charles Steenbergen, John W Harmon, Harry C Dietz, Kathleen L Gabrielson, David A Kass, Gregg L Semenza.   

Abstract

Chronic systemic hypertension causes cardiac pressure overload leading to increased myocardial O(2) consumption. Hypoxia-inducible factor 1 (HIF-1) is a master regulator of O(2) homeostasis. Mouse embryos lacking expression of the O(2)-regulated HIF-1α subunit die at midgestation with severe cardiac malformations and vascular regression. Here we report that Hif1a(f/f);Tie2-Cre conditional knockout mice, which lack HIF-1α expression only in Tie2(+) lineage cells, develop normally, but when subjected to pressure overload induced by transaortic constriction (TAC), they manifest rapid cardiac decompensation, which is accompanied by excess cardiac fibrosis and myocardial hypertrophy, decreased myocardial capillary density, increased myocardial hypoxia and apoptosis, and increased TGF-β signaling through both canonical and noncanonical pathways that activate SMAD2/3 and ERK1/2, respectively, within endothelial cells of cardiac blood vessels. TAC also induces dilatation of the proximal aorta through enhanced TGF-β signaling in Hif1a(f/f);Tie2-Cre mice. Inhibition of TGF-β signaling by treatment with neutralizing antibody or pharmacologic inhibition of MEK-ERK signaling prevented TAC-induced contractile dysfunction and pathological remodeling. Thus, HIF-1 plays a critical protective role in the adaptation of the heart and aorta to pressure overload by negatively regulating TGF-β signaling in endothelial cells. Treatment of wild-type mice with digoxin, which inhibits HIF-1α synthesis, resulted in rapid cardiac failure after TAC. Although digoxin has been used for decades as an inotropic agent to treat heart failure, it does not improve survival, suggesting that the countertherapeutic effects of digoxin observed in the TAC mouse model may have clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403061      PMCID: PMC3325701          DOI: 10.1073/pnas.1202081109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia.

Authors:  Tarak H Patel; Hideo Kimura; Clifford R Weiss; Gregg L Semenza; Lawrence V Hofmann
Journal:  Cardiovasc Res       Date:  2005-10-01       Impact factor: 10.787

2.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Authors:  Eiki Takimoto; Hunter C Champion; Manxiang Li; Diego Belardi; Shuxun Ren; E Rene Rodriguez; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  Nat Med       Date:  2005-01-23       Impact factor: 53.440

Review 3.  Digoxin - time to take the gloves off?

Authors:  Emma Eade; Rebecca Cooper; Andrew R J Mitchell
Journal:  Int J Cardiol       Date:  2011-07-31       Impact factor: 4.164

4.  Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Authors:  Jennifer P Habashi; Daniel P Judge; Tammy M Holm; Ronald D Cohn; Bart L Loeys; Timothy K Cooper; Loretha Myers; Erin C Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R Neptune; Marc K Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B Rifkin; Luca Carta; Francesco Ramirez; David L Huso; Harry C Dietz
Journal:  Science       Date:  2006-04-07       Impact factor: 47.728

5.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.

Authors:  Masanori Sano; Tohru Minamino; Haruhiro Toko; Hideyuki Miyauchi; Masayuki Orimo; Yingjie Qin; Hiroshi Akazawa; Kaoru Tateno; Yosuke Kayama; Mutsuo Harada; Ippei Shimizu; Takayuki Asahara; Hirofumi Hamada; Shuhei Tomita; Jeffrey D Molkentin; Yunzeng Zou; Issei Komuro
Journal:  Nature       Date:  2007-03-04       Impact factor: 49.962

Review 6.  Tackling heart failure in the twenty-first century.

Authors:  James O Mudd; David A Kass
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

Review 7.  Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia.

Authors:  Ralph V Shohet; Joseph A Garcia
Journal:  J Mol Med (Berl)       Date:  2007-11-20       Impact factor: 4.599

8.  Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha.

Authors:  Zheqing Cai; Hua Zhong; Marta Bosch-Marce; Karen Fox-Talbot; Lei Wang; Chiming Wei; Michael A Trush; Gregg L Semenza
Journal:  Cardiovasc Res       Date:  2007-10-11       Impact factor: 10.787

9.  Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease.

Authors:  Mark A Hlatky; Thomas Quertermous; Derek B Boothroyd; James R Priest; Alec J Glassford; Richard M Myers; Stephen P Fortmann; Carlos Iribarren; Holly K Tabor; Themistocles L Assimes; Robert J Tibshirani; Alan S Go
Journal:  Am Heart J       Date:  2007-09-18       Impact factor: 4.749

10.  Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia.

Authors:  Marta Bosch-Marce; Hiroaki Okuyama; Jacob B Wesley; Kakali Sarkar; Hideo Kimura; Ye V Liu; Huafeng Zhang; Marianne Strazza; Sergio Rey; Lindsey Savino; Yi Fu Zhou; Karin R McDonald; Youn Na; Scott Vandiver; Alireza Rabi; Yuval Shaked; Robert Kerbel; Theresa Lavallee; Gregg L Semenza
Journal:  Circ Res       Date:  2007-10-11       Impact factor: 17.367

View more
  54 in total

1.  Pharmacological inhibition of TGFβ receptor improves Nkx2.5 cardiomyoblast-mediated regeneration.

Authors:  Wen-Pin Chen; Yuan-Hung Liu; Yi-Jin Ho; Sean M Wu
Journal:  Cardiovasc Res       Date:  2014-10-31       Impact factor: 10.787

2.  The NuRD chromatin-remodeling complex enzyme CHD4 prevents hypoxia-induced endothelial Ripk3 transcription and murine embryonic vascular rupture.

Authors:  Sarah Colijn; Siqi Gao; Kyle G Ingram; Matthew Menendez; Vijay Muthukumar; Robert Silasi-Mansat; Joanna J Chmielewska; Myron Hinsdale; Florea Lupu; Courtney T Griffin
Journal:  Cell Death Differ       Date:  2019-06-24       Impact factor: 15.828

3.  Comprehensive transcriptomic profiling reveals SOX7 as an early regulator of angiogenesis in hypoxic human endothelial cells.

Authors:  Jeff Klomp; James Hyun; Jennifer E Klomp; Kostandin Pajcini; Jalees Rehman; Asrar B Malik
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

4.  Kidney injury is independent of endothelial HIF-1α.

Authors:  Joanna Kalucka; Gunnar Schley; Adela Georgescu; Bernd Klanke; Susanne Rössler; Jasmin Baumgartl; Joachim Velden; Kerstin Amann; Carsten Willam; Randall S Johnson; Kai-Uwe Eckardt; Alexander Weidemann
Journal:  J Mol Med (Berl)       Date:  2015-03-11       Impact factor: 4.599

5.  Overexpression of hexokinase 2 reduces mitochondrial calcium overload in coronary endothelial cells of type 2 diabetic mice.

Authors:  Minglin Pan; Ying Han; Aninda Basu; Anzhi Dai; Rui Si; Conor Willson; Angela Balistrieri; Brian T Scott; Ayako Makino
Journal:  Am J Physiol Cell Physiol       Date:  2018-03-07       Impact factor: 4.249

6.  FOXE3 mutations predispose to thoracic aortic aneurysms and dissections.

Authors:  Shao-Qing Kuang; Olga Medina-Martinez; Dong-Chuan Guo; Limin Gong; Ellen S Regalado; Corey L Reynolds; Catherine Boileau; Guillaume Jondeau; Siddharth K Prakash; Callie S Kwartler; Lawrence Yang Zhu; Andrew M Peters; Xue-Yan Duan; Michael J Bamshad; Jay Shendure; Debbie A Nickerson; Regie L Santos-Cortez; Xiurong Dong; Suzanne M Leal; Mark W Majesky; Eric C Swindell; Milan Jamrich; Dianna M Milewicz
Journal:  J Clin Invest       Date:  2016-02-08       Impact factor: 14.808

7.  Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.

Authors:  Shao-Qing Kuang; Liang Geng; Siddharth K Prakash; Jiu-Mei Cao; Steven Guo; Carlos Villamizar; Callie S Kwartler; Andrew M Peters; Allan R Brasier; Dianna M Milewicz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-18       Impact factor: 8.311

8.  Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation.

Authors:  M Abu-Remaileh; R I Aqeilan
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

Review 9.  Hypoxia-inducible factor 1 and cardiovascular disease.

Authors:  Gregg L Semenza
Journal:  Annu Rev Physiol       Date:  2013-08-21       Impact factor: 19.318

10.  Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.

Authors:  Andrew J Bryant; Ryan P Carrick; Melinda E McConaha; Brittany R Jones; Sheila D Shay; Christy S Moore; Thomas R Blackwell; Santhi Gladson; Niki L Penner; Ankita Burman; Harikrishna Tanjore; Anna R Hemnes; Ayub K Karwandyar; Vasiliy V Polosukhin; Megha A Talati; Hui-Jia Dong; Linda A Gleaves; Erica J Carrier; Christa Gaskill; Edward W Scott; Susan M Majka; Joshua P Fessel; Volker H Haase; James D West; Timothy S Blackwell; William E Lawson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-04       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.